Amgen (AMGN) announced full results from Part 1 of the Phase 2 study for MariTide in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha in cardiovascular disease and the VESALIUS-REAL study of real-world lipid management patterns at the 85th American Diabetes Association Scientific Sessions taking place from June 20-23, 2025, in Chicago. Data for MariTide, an investigational long-acting peptide-antibody conjugate subcutaneously administered monthly or less frequently, will be presented during a symposium being held on Monday, June 23 from 1:30 p.m. – 3:00 p.m. CDT. The Symposium will highlight 52-week efficacy, safety and tolerability data from Part 1 of the Phase 2 study, complete data from the primary analysis of the Phase 1 pharmacokinetics low dose initiation study, and additional information on the Phase 3 MARITIME Chronic Weight Management studies. Topline results from Part 1 of the Phase 2 study were announced in November 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Strong Growth Potential and Strategic Initiatives Support Buy Rating
- Amgen’s Resilience and Growth Potential: Strong Revenue, Promising Pipeline, and Positive Outlook
- Amgen presents new interim results from the global Phase 3 DeLLphi-304 trial
- Amgen’s Strong Market Position and Growth Potential Drive Buy Rating
- Amgen assumed with a Neutral at Guggenheim
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue